Quarterly report · Q2
9776.TEDINET S100S73T
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥20.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥10.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥291m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥493m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥296m | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥589m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥386m | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥508m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥226m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥569m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥258m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥226m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥319m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥16.7bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥16.5bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥16.2bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.7bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥5.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥11.0bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥10.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.5bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.1bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.7bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥810m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥674m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥171m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥409m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥292m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥238m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥348m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥223m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥67.94 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.23 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥170.53 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥77.37 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥54.09 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 64.4% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.2% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥58m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥56m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥41m |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥78m |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥377m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥798m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥492m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥306m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥7m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.1bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥9.8bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥306m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥448m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥10.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥9.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥308m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥489m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥46m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥44m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥30m |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥371m |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥356m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥805m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥472m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥333m |
| jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥6m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.3bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥9.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥333m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥721m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥10.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥334m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥751m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 549
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 1185000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.3561 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 210000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0633 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 171000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0516 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 169000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0510 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 126000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0380 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 113000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0340 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 113000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0340 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 103000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0311 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 95000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0285 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 66000 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0200 | |
| Number of shares held | CurrentQuarterInstant | 2356000 | |
| Shareholding ratio | CurrentQuarterInstant | 0.7075 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 885400 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 3329700 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 33297 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 900 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 4216000 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 33297 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 885400 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 885400 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.2100 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 885400 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 885400 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.2100 | |
| Cash and deposits | Prior1YearInstant | 3664081000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 4065118000 | JPY |
| Notes and accounts receivable trade and contract assets | Prior1YearInstant | 2947145000 | JPY |
| Notes and accounts receivable trade and contract assets | CurrentQuarterInstant | 2968246000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 431748000 | JPY |
| Merchandise and finished goods | CurrentQuarterInstant | 483904000 | JPY |
| Work in process | Prior1YearInstant | 20215000 | JPY |
| Work in process | CurrentQuarterInstant | 11322000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 62760000 | JPY |
| Raw materials and supplies | CurrentQuarterInstant | 60171000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |